Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology ...

Insulin resistance precedes and predicts the onset of type 2 diabetes mellitus (DM2), a chronic disease that causes high ...

Cogent Biosciences (NASDAQ:COGT – Get Free Report) is projected to release its earnings data before the market opens on ...

The introduction of anti-VEGF agents has revolutionized the field of medical retina care by reducing rates of vision loss and ...

Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...

A phase III study testing the role of proactive coaching on patient reported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib or a combination of axitinib + pembrolizumab ...

Equities research analysts at StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) in a report issued on Sunday. The firm set a “hold” rating on the stock ...

Sellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) ...

The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application for zongertinib for the treatment of adult patients with ...